1、关于使用闲置资金购买银行理财产品的议案 内容详见公司在上海证券交易所网站（www.sse.com.cn）发布的《关于使用闲置资金购买银行理财产品 的公告》（公告编号：临2025-062号）。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600535 证券简称：天士力 编号：临2025-061号 天士力医药集团股份有限公司 第九届董事会第14次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 天士力医药集团股份有限公司（以下简称"公司"）第九届董事会第14次会议通知于2025年9月12日以书 面方式发出，会议于2025年9月17日下午13:30在公司会议室以现场会议方式召开，会议应到董事15人， 实到13人，董事王亮先生因工作原因书面委托董事王克先生代为行使表决权，董事原京先生因工作原因 书面委托董事席凯先生代为行使表决权，公司部分高管列席会议。会议符合《公司法》和《公司章程》 的有关规定，会议合法、有效。会议由公司董事长周辉女士主持，经与会人员逐项审议，通过了以下议 案： 表决情况为：有效 ...

证券代码：600535 证券简称：天士力 编号：临2025-062号 天士力医药集团股份有限公司 关于使用闲置资金购买银行理财产品的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 基本情况 | 投资金额 | 不超过 亿元人民币 30 | | --- | --- | | 投资种类 | 银行及其下属理财子公司中低风险收益型理财产品（产品类型为 | | | 固定收益类非保本浮动收益型，风险评级为R2以内产品（含R2）） | | | 和银行结构性存款，资金不会直接投资证券市场产品股票、债券、 | | | 基金、外汇及其衍生产品等高风险产品。 | | 资金来源 | 自有资金 | 已履行及拟履行的审议程序 天士力医药集团股份有限公司（以下简称"公司"）于 2025 年 9 月 17 日召 开第九届董事会第 14 次会议，审议通过了《关于使用闲置资金购买银行理财产品 的议案》，本议案尚需提交公司股东大会审议。 特别风险提示 公司拟购买的理财产品虽为中低风险收益型理财产品和银行结构性存款，但金 融市场受宏观经济、财 ...

召开地点：天津市北辰科技园区天士力现代中药城天士力医药集团股份有限 公司会议室 证券代码：600535 证券简称：天士力 编号：临2025-063号 天士力医药集团股份有限公司 关于召开2025年第五次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一)股东大会类型和届次 2025年第五次临时股东大会 召开的日期时间：2025 年 10 月 10 日 15 点 30 分 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 10 月 10 日 至2025 年 10 月 10 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互 联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 (六) 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 1 股 ...

内容详见公司在上海证券交易所网站（www.sse.com.cn）发布的《关于召开 2025 年第五次临时股东大会的通知》（公告编号：临 2025-063 号）。 证券代码：600535 证券简称：天士力 编号：临 2025-061 号 天士力医药集团股份有限公司 第九届董事会第 14 次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 天士力医药集团股份有限公司（以下简称"公司"）第九届董事会第 14 次会 议通知于 2025 年 9 月 12 日以书面方式发出，会议于 2025 年 9 月 17 日下午 13:30 在公司会议室以现场会议方式召开，会议应到董事 15 人，实到 13 人，董事王亮 先生因工作原因书面委托董事王克先生代为行使表决权，董事原京先生因工作原 因书面委托董事席凯先生代为行使表决权，公司部分高管列席会议。会议符合《公 司法》和《公司章程》的有关规定，会议合法、有效。会议由公司董事长周辉女 士主持，经与会人员逐项审议，通过了以下议案： 1、关于使用闲置资金购买银行理财产品的议案 内容详见 ...

Group 1 - The company Tian Shi Li announced on September 17 that it will hold the 14th meeting of the 9th Board of Directors on September 17, 2025, to approve the proposal to use idle funds to purchase bank wealth management products, with a maximum investment of 3 billion RMB [1] - The funds can be used on a rolling basis within the approved limit, and the transaction amount at any point during the investment period, including reinvested earnings, shall not exceed 3 billion RMB [1] - As of the report date, the market capitalization of Tian Shi Li is 23.8 billion RMB [1] Group 2 - For the fiscal year 2024, the revenue composition of Tian Shi Li is as follows: Traditional Chinese medicine accounts for 70.89%, chemical preparations 15.38%, pharmaceutical commerce 10.53%, biological drugs 2.25%, and chemical raw materials 0.61% [1]

Core Points - The Medical Health R Index (480016) closed at 8278.77 points, down 0.33%, with a trading volume of 31.765 billion yuan and a turnover rate of 1.08% [1] - Among the index constituents, 18 stocks rose while 31 fell, with Yirui Technology leading the gainers at a 4.4% increase and Zexin Pharmaceutical leading the decliners at a 5.37% decrease [1] Index Constituents Summary - The top ten constituents of the Medical Health R Index include: - WuXi AppTec (sh603259) with a weight of 13.58% and a market cap of 315.96 billion yuan [1] - Hengrui Medicine (sh600276) with a weight of 10.87% and a market cap of 458.96 billion yuan [1] - Mindray Medical (sz300760) with a weight of 8.17% and a market cap of 290.50 billion yuan [1] - United Imaging Healthcare (sh688271) with a weight of 4.14% and a market cap of 126.08 billion yuan [1] - Other notable constituents include Pianzai Shou (sh600436), Yierfu Technology (sz300015), Kelun Pharmaceutical (sz002422), New Hope Liuhe (sz002001), Fosun Pharma (sh600196), and East China Pharmaceutical (sz000963) [1] Capital Flow Analysis - The net outflow of main funds from the index constituents totaled 1.638 billion yuan, while retail investors saw a net inflow of 1.098 billion yuan [1] - Notable capital flows include: - Kailai Ying (002821) with a main fund net inflow of 101 million yuan [2] - Mindray Medical (300760) with a main fund net inflow of approximately 90.77 million yuan [2] - Yuyue Medical (002223) with a main fund net inflow of 24.60 million yuan [2]

Group 1 - The company has provided a guarantee of 400 million RMB for its subsidiary Tianjin Tianshili Pharmaceutical Commercial Co., Ltd., which is a wholly-owned subsidiary of Tianshili Pharmaceutical Group Co., Ltd. [2][4] - The guarantee was approved during the company's board meeting and aims to support the financing needs of Tianshili's subsidiaries, with a total expected guarantee amount of up to 900 million RMB for the year 2025 [3][8] - The guarantee agreement with Minsheng Bank Tianjin Branch includes a maximum guarantee limit of 400 million RMB, and the credit status of the guaranteed party is reported to be good [4][5] Group 2 - The company has no overdue guarantees and the current guarantee is within the previously estimated limit [5] - The guaranteed company, Tianjin Tianshili Pharmaceutical Commercial Co., Ltd., has an asset-liability ratio exceeding 70%, which is noted as a risk factor for investors [5] - As of the announcement date, the total external guarantee amount for the company's subsidiaries is 1.35615 billion RMB, accounting for 6.81% of the company's latest audited net assets [8]

Core Viewpoint - The company has announced a guarantee for its wholly-owned subsidiary, aimed at enhancing financing efficiency and reducing costs, with a total guarantee amount not exceeding RMB 900 million for the year 2025 [2][5]. Group 1: Guarantee Details - The company signed a maximum guarantee contract with Minsheng Bank Tianjin Branch on September 15, 2025, providing a joint liability guarantee of RMB 400 million for its pharmaceutical business [2]. - The company has approved a total guarantee amount of up to RMB 900 million for its wholly-owned subsidiaries, including Jiangsu Hongtai Pharmaceutical Co., Ltd. [2][5]. - As of the announcement date, the total balance of guarantees provided by the company to its subsidiaries is RMB 957 million, accounting for 8.04% of the company's latest audited net assets [5]. Group 2: Subsidiary Information - The guaranteed subsidiary has a good credit status and is not listed as a dishonest executor, indicating a stable financial condition [3]. - The company is able to monitor the daily operations, credit status, cash flow, and financial changes of the guaranteed subsidiary, which helps in managing risks effectively [5]. Group 3: Necessity and Reasonableness of the Guarantee - The guarantee aligns with the company's operational needs and overall development strategy, contributing to improved financing efficiency and reduced costs [5]. - The board of directors believes that the overall risk associated with the guarantee is controllable and does not harm the interests of the company and its shareholders [5].

证券代码：600535 证券简称：天士力 编号：临2025-060号 天士力医药集团股份有限公司 关于为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 担保对象及基本情况 注：上述被担保人为天士力医药集团股份有限公司（以下简称"公司"）下 属全资子公司，不存在关联担保。 累计担保情况 | 对外担保逾期的累计金额（万元） | | 0 | | --- | --- | --- | | 截至本公告日上市公司及其控股子 | | 0 | | 公司对外担保总额（万元） | | | | 对外担保总额占上市公司最近一期 经审计净资产的比例（%） | | 0 | | | □对外担保总额（含本次）超过上市公司最近一 | | | | 期经审计净资产 50% □对外担保总额（含本次）超过上市公司最近一 | | | 特别风险提示 | 期经审计净资产 100% | | | | □对合并报表外单位担保总额（含本次）达到或 | | | | 超过最近一期经审计净资产 30% | | | | 本次对资产负债率超过 ...

Core Viewpoint - The pharmaceutical industry is experiencing a phase of performance divergence, with leading companies showing positive trends while many others face significant declines in performance. Overall, the industry's performance in the first half of 2025 is not impressive, with a revenue of 1.23 trillion yuan, down 1.2% year-on-year, and a total profit of 176.69 billion yuan, down 2.8% year-on-year. However, there is a clear trend of transformation from "generic" to "innovative" drugs, with many companies emphasizing technological innovation as a key strategy for high-quality development [1][2][3]. Industry Performance - In the first half of 2025, the pharmaceutical manufacturing industry reported a revenue of 1.23 trillion yuan, a year-on-year decrease of 1.2%, and a total profit of 176.69 billion yuan, down 2.8% year-on-year [1]. - Nearly 70 listed traditional Chinese medicine companies reported positive revenue and net profit, but over half experienced a year-on-year decline in net profit [2]. Performance Divergence - There is a notable divergence in performance among pharmaceutical companies. In the first half of 2025, 10 companies reported a net profit growth exceeding 100%, with the highest being Teva Pharmaceutical at 1313%. Conversely, 6 companies saw a net profit decline exceeding 100%, with the largest drop being 702% [3]. - Key drivers for improved performance include significant sales recovery of core products, enhanced cost control, and new product acquisitions through R&D, partnerships, or mergers [3]. R&D Investment Trends - Many leading pharmaceutical companies have significantly increased their R&D investments. For instance, China Resources Sanjiu's R&D investment reached 662 million yuan in the first half of 2025, a year-on-year increase of 68.99%. Yiling Pharmaceutical invested 399 million yuan, accounting for 9.87% of its revenue [3][4]. - Sales expenses for many companies have decreased, with a total of 492 A-share pharmaceutical companies reporting sales expenses of 159.49 billion yuan, down 3.72% year-on-year [4]. Policy Support for Innovation - The Chinese government has been actively supporting the development of innovative drugs, with 210 innovative drugs and 269 innovative medical devices approved during the 14th Five-Year Plan period, showing a trend of accelerated growth [5][7]. - In the first half of 2025, the National Medical Products Administration approved 43 innovative drugs, with 40 developed by domestic companies [7]. Strategic Focus on Innovation - Innovation has become a core strategy for many pharmaceutical companies, with several firms explicitly stating their commitment to increasing innovation efforts in their 2025 semi-annual reports. For example, China Resources Sanjiu has emphasized a dual strategy of "brand + innovation" [8]. - Companies like Teva Pharmaceutical and Taiji Group are focusing on key areas and the development of innovative traditional Chinese medicine, enhancing their competitiveness in the innovative drug sector [10]. Mergers and Acquisitions - The pharmaceutical industry has seen an increase in mergers and acquisitions, particularly following the "six merger rules" introduced in September 2024. Companies like China Resources Sanjiu and Kangyuan Pharmaceutical have actively pursued acquisitions to enhance their innovative drug capabilities [12][13]. - China Resources Sanjiu's acquisition of Teva Pharmaceutical for over 6.2 billion yuan has positioned it as a major player in the innovative drug sector, with expected synergies enhancing long-term growth potential [13][15]. Future Outlook - The pharmaceutical industry is undergoing structural adjustments and is expected to maintain resilience and vitality due to factors such as an aging population and ongoing health initiatives. The shift from "single-driven" to "dual-driven" strategies, focusing on both traditional and innovative drugs, is anticipated to drive future growth [15].